ALN CC5

Drug Profile

ALN CC5

Alternative Names: ALN-CC5

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Oligonucleotides; Small interfering RNA
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Paroxysmal nocturnal haemoglobinuria
  • Preclinical Haemolytic uraemic syndrome; Myasthenia gravis

Most Recent Events

  • 05 Dec 2016 Sanofi Genzyme elects not to opt-in to develop and commercialise ALN CC5
  • 05 Dec 2016 Updated pharmacodynamics, adverse events and drug interactions data from a phase I/II trial in Paroxysmal nocturnal haemoglobinuria presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 23 Nov 2016 Alnylam terminates a phase II trial in Paroxysmal nocturnal haemoglobinuria (Treatment experienced) in Spain (SC) (EudraCT2016-002943-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top